Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
SION 
Sionna Therapeutics, Inc. Common Stock (SION)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/17/2025: SION (4-star) is a STRONG-BUY. BUY since 18 days. Simulated Profits (17.91%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $38.5
1 Year Target Price $38.5
| 3 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 80.94% | Avg. Invested days 45 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 10/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 768.97M USD | Price to earnings Ratio - | 1Y Target Price 38.5 |
Price to earnings Ratio - | 1Y Target Price 38.5 | ||
Volume (30-day avg) 3 | Beta - | 52 Weeks Range 7.25 - 34.00 | Updated Date 09/27/2025 |
52 Weeks Range 7.25 - 34.00 | Updated Date 09/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.5 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 477933038 | Price to Sales(TTM) - |
Enterprise Value 477933038 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 44092100 | Shares Floating 11223207 |
Shares Outstanding 44092100 | Shares Floating 11223207 | ||
Percent Insiders 7.2 | Percent Institutions 93.43 |
Upturn AI SWOT
Sionna Therapeutics, Inc. Common Stock
Company Overview
History and Background
Sionna Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for cystic fibrosis (CF). It was founded in 2019 and is headquartered in Boston, Massachusetts. Sionna is dedicated to transforming the lives of people with CF by developing novel small molecules designed to selectively inhibit the cystic fibrosis transmembrane conductance regulator (CFTR). The company has rapidly advanced its programs from discovery to clinical development.
Core Business Areas
- CFTR Modulator Development: Sionna focuses on the discovery, development, and commercialization of novel CFTR modulators that can address the unmet needs of people with CF who do not benefit from existing therapies. They have a portfolio of small molecules with differentiated mechanisms of action.
Leadership and Structure
Sionna Therapeutics is led by a team of experienced biotech executives and scientists. Bridget Ou2019Hara Navin is the CEO. The company has a board of directors that provides strategic oversight.
Top Products and Market Share
Key Offerings
- SION-638: SION-638 is Sionna's lead drug candidate, a novel small molecule IICorrector. It is currently in clinical development for CF. There is currently no market share because the drug is still in clinical trials. Competitors include Vertex Pharmaceuticals with their existing CFTR modulators (Trikafta, Orkambi, Kalydeco, Symdeko) and other companies developing next-generation CFTR modulators.
Market Dynamics
Industry Overview
The cystic fibrosis therapeutics market is a significant and growing market driven by the prevalence of CF and the advancements in treatment options. The market is dominated by CFTR modulators, which improve the function of the defective CFTR protein. While existing therapies have significantly improved the lives of many people with CF, there remains a substantial unmet need, particularly for patients with certain genetic mutations or those who do not respond well to current treatments.
Positioning
Sionna is positioned as a company developing next-generation CFTR modulators to address the unmet needs of people with CF, specifically those who do not respond well to or are ineligible for existing therapies. Their competitive advantage lies in their differentiated approach and novel small molecule drug candidates.
Total Addressable Market (TAM)
The global cystic fibrosis market size was valued at USD 7.94 billion in 2023 and is expected to grow to USD 19.69 billion by 2032. Sionna is positioned to capture a portion of this market by developing new therapies for patients who don't respond to current treatments or can't take them.
Upturn SWOT Analysis
Strengths
- Novel CFTR modulator development approach
- Strong scientific team with expertise in CF
- Focus on addressing unmet needs in CF
- Lead candidate in clinical development
Weaknesses
- Early-stage company with limited resources
- Single therapeutic focus (CF)
- Clinical trial risk
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline to other CF-related targets
- Positive clinical trial results
- Potential for orphan drug designation and market exclusivity
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- VRTX
Competitive Landscape
Sionna faces significant competition from Vertex Pharmaceuticals, which currently dominates the CFTR modulator market. Sionna aims to differentiate itself by developing therapies that address unmet needs for patients who do not respond well to existing treatments.
Growth Trajectory and Initiatives
Historical Growth: Sionna Therapeutics has grown rapidly since its founding in 2019, advancing its lead candidate into clinical development.
Future Projections: Future growth will depend on the successful completion of clinical trials and potential commercialization of SION-638.
Recent Initiatives: Recent initiatives include advancing SION-638 through clinical trials and expanding their pipeline of CFTR modulators.
Summary
Sionna Therapeutics is a promising clinical-stage biopharmaceutical company focused on developing novel therapies for cystic fibrosis. The company's lead candidate, SION-638, is currently in clinical development and has the potential to address the unmet needs of patients who do not respond well to existing treatments. The company faces competition from established pharmaceutical companies and is dependent on successful clinical trial outcomes. However, its novel approach and strong scientific team position it for potential growth in the CF market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Sionna Therapeutics Website
- Company Press Releases
- Industry Reports
- SEC Filings
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is approximate and may vary depending on the source. Financial data is based on publicly available information and analyst estimates.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sionna Therapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2025-02-07 | President, CEO & Director Mr. Michael Cloonan M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 41 | Website https://www.sionnatx.com |
Full time employees 41 | Website https://www.sionnatx.com | ||
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; and SION-719 and SION-451, which are nucleotide-binding domain 1 stabilizers in Phase 1 trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.